Portage Biotech Inc represents a strong commitment to innovation, scientific excellence, and patient-centricity. As a leading biotechnology company, Portage Biotech is dedicated to discovering and developing breakthrough therapies to address unmet medical needs. Their corporate philosophy centers around collaboration, transparency, and ethical practices, ensuring the highest standards of integrity in all aspects of their research and business operations. Portage Biotech embraces a patient-first approach, striving to improve the lives of individuals and contribute to advancements in healthcare through their cutting-edge drug development programs.

Portage Biotech Inc is primarily present in the United States, Canada, and Europe. With offices and operations in these countries and regions, Portage Biotech Inc extends its reach and presence in the global biotech market. This multinational presence allows the company to tap into various markets, collaborate with international partners, and access a diverse pool of resources and expertise. With a firm foothold in these key locations, Portage Biotech Inc is well-positioned to drive innovation, facilitate research and development, and deliver cutting-edge biotech solutions worldwide.

Portage Biotech Inc has achieved several significant milestones. These include successfully advancing their pipeline of novel immunotherapy and targeted therapy candidates, securing partnerships with leading pharmaceutical companies for the development and commercialization of their products, and obtaining regulatory approvals for clinical trials. The company has also demonstrated promising results in early-stage studies, showcasing their potential for addressing unmet medical needs. With a strong focus on innovation and collaboration, Portage Biotech Inc continues to strive towards enhancing patient outcomes and making a meaningful impact in the field of biotechnology.

Portage Biotech Inc, a leading clinical-stage biopharmaceutical company, has a rich history and compelling background. Established in [year], Portage Biotech has been dedicated to discovering and developing innovative therapies that address unmet medical needs. With a focus on oncology and immunology, the company aims to deliver groundbreaking advancements in cancer treatment and autoimmune diseases. Portage Biotech's team of industry experts and seasoned scientists bring a wide range of experience to the table, leveraging cutting-edge research and strategic partnerships to advance their mission. As a result, Portage Biotech Inc has become a respected name in the biotechnology sector, consistently working towards improving patients' lives through their revolutionary therapies.

The main competitors of Portage Biotech Inc in the market include prominent biopharmaceutical companies such as Pfizer, Johnson & Johnson, Novartis, Roche, and AstraZeneca. These companies are also engaged in developing innovative biotech solutions and therapies, posing competition to Portage Biotech Inc.

Portage Biotech Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Portage Biotech Inc is focused on the development and commercialization of innovative therapeutics to address significant unmet medical needs. The company primarily focuses on advancing its portfolio of immuno-oncology assets, aiming to bring novel treatments to patients with various types of cancer. Portage Biotech Inc strives to identify and acquire promising drug candidates or early-stage technologies with strong therapeutic potential. Through strategic collaborations and partnerships, the company aims to accelerate the development and ultimately obtain regulatory approvals for its pipeline products. By capitalizing on novel scientific advancements, Portage Biotech Inc aims to revolutionize the treatment landscape and improve patient outcomes in the field of oncology.

Raportul Portage Biotech preț/beneficiu este -0,19.

Raportul Portage Biotech preț/vânzări este 0.

Scorul de calitate AlleAktien pentru Portage Biotech este 4/10.

Cifra de afaceri nu poate fi calculată în prezent pentru Portage Biotech.

Profitul așteptată Portage Biotech este -13,11 milioane USD.

Portage Biotech Inc is an innovative biotechnology company focused on developing therapeutic products to combat diseases such as cancer, Alzheimer's, and Parkinson's. The company's business model is based on a specialized pipeline of product candidates developed by a highly qualified team of leading scientists, biotechnology engineers, and clinical experts. Portage Biotech operates in multiple divisions, including Portage Pharmaceuticals, Portage BioAnalytics, and Biohaven Pharmaceuticals. The company's portfolio includes groundbreaking products such as PPL-003, BNC210, and Trastuzumab Biosimilar. Portage Biotech utilizes innovative technologies and collaborations to develop solutions and advance groundbreaking medications. The company aims to continually innovate its products and meet the needs of patients and customers worldwide, making it a significant player in the biotechnology sector.

Portage Biotech distribuie un dividend de 0 USD în plăți anuale.

Dividenda nu poate fi calculată în prezent pentru Portage Biotech sau compania nu distribuie dividende.

Codul ISIN pentru Portage Biotech este VGG7185A1286.

Codul WKN al Portage Biotech este A2P6BP.

Ticker-ul pentru Portage Biotech este PRTG.

În ultimele 12 luni, Portage Biotech a plătit un dividend în valoare de . Aceasta corespunde unei randamente a dividendului de aproximativ . Pentru următoarele 12 luni, Portage Biotech va plăti probabil un dividend de 0 USD.

Randamentul dividendelor pentru Portage Biotech este în prezent de .

Portage Biotech plătește un dividend trimestrial. Acesta este distribuit în lunile .

Portage Biotech a plătit dividende în fiecare an, în ultimii 0 ani.

Pentru următoarele 12 luni se așteaptă dividende în valoare de 0 USD. Acest lucru corespunde unei randamente a dividendelor de 0 %.

Portage Biotech este atribuit sectorului 'Sănătate'.

Pentru a primi ultimul dividend de Portage Biotech de la 07.08.2024 în valoare de 0 USD, trebuia să deții acțiunea în portofoliu înainte de ziua Ex-Tag de pe 07.08.2024.

Ultima plată a dividendului a fost efectuată la 07.08.2024.

În anul 2023, Portage Biotech a distribuit 0 USD sub formă de dividende.

Dividendele de la Portage Biotech sunt distribuite în USD.